Guidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer's disease

被引:18
作者
Schachter, AS [1 ]
Davis, KL [1 ]
机构
[1] Mt Sinai Sch Med, Dept Psychiat, Mt Sinai Med Ctr, New York, NY 10029 USA
关键词
D O I
10.2165/00023210-199911040-00004
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The cholinesterase inhibitors are the only available scientifically proven symptomatic treatments for dementia of the Alzheimer's type. The guidelines we present summarise the current updated knowledge on the available drugs, including tacrine, donepezil, rivastigmine, metrifonate and galantamine (galanthamine). Each of these drugs have been proven to be more effective than placebo in improving symptoms in well designed, double-blind, placebo-controlled studies. Although tacrine was the first drug approved by the US Food and Drug Administration, it needs frequent monitoring of alanine amino transferase levels. Hence, donepezil emerged as a frequently prescribed drug for dementia of the Alzheimer's type, secondary to its ease of use and lack of significant adverse effects. More studies are needed regarding long term efficacy, head-to-head comparisons and effects upon behavioural disturbances in dementia of the Alzheimer's type. These guidelines will provide the starting point for a wider clinical use because, although available and clinically effective, the cholinesterase inhibitors are under-prescribed by clinicians in the pharmacological treatment of Alzheimer's disease.
引用
收藏
页码:281 / 288
页数:8
相关论文
共 36 条
[1]  
ANAND R, 1996, J DRUG DEV CLIN PR, V8, P1
[2]   Effects of metrifonate on cognitive decline in Alzheimer disease: A double-blind, placebo-controlled, 6-month study [J].
Becker, RE ;
Colliver, JA ;
Markwell, SJ ;
Moriearty, PL ;
Unni, LK ;
Vicari, S .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1998, 12 (01) :54-57
[3]   Double-blind placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease [J].
Becker, RE ;
Colliver, JA ;
Markwell, SJ ;
Moriearty, PL ;
Unni, LK ;
Vicari, S .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1996, 10 (03) :124-131
[4]  
BIERER LM, 1995, J NEUROCHEM, V64, P749
[5]  
Bores GM, 1996, J PHARMACOL EXP THER, V277, P728
[6]  
Crismon ML, 1998, PHARMACOTHERAPY, V18, P47
[7]  
CUMMINGS J, 1996, ALZHEIMERS DIS RELAT, V17, pS153
[8]   PHYSOSTIGMINE AMELIORATES THE DELUSIONS OF ALZHEIMERS-DISEASE [J].
CUMMINGS, JL ;
GORMAN, DG ;
SHAPIRA, J .
BIOLOGICAL PSYCHIATRY, 1993, 33 (07) :536-541
[9]   Metrifonate treatment of the cognitive deficits of Alzheimer's disease [J].
Cummings, JL ;
Cyrus, PA ;
Bieber, F ;
Mas, J ;
Orazem, J ;
Gulanski, B .
NEUROLOGY, 1998, 50 (05) :1214-1221
[10]  
Cummings JL, 1998, PHARMACOTHERAPY, V18, P43